ICCM Share Price Performance
Recent ICCM News & Updates
No updates
IceCure Medical Ltd Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.21
- Gross Margin
- 42.77%
- Net Profit Margin
- -467.37%
- Debt/Equity Ratio
- 0%
IceCure Medical Ltd Competitors
About ICCM
- Founded
- 2006
- Employees
- 65
- CEO
- WebsiteView website
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Israeli Market Performance
- 7 Days: -1.5%
- 3 Months: 21.3%
- 1 Year: 66.8%
- Year to Date: 28.8%
Over the last 7 days, the market has dropped 1.5%, driven by a loss of 1.9% in the Financials sector. As for the longer term, the market has actually risen by 67% in the last year. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading